Merck MK-869
Substance P antagonist MK-869 (L-754,030) will be studied in a Phase III clinical trial for prevention of chemotherapy-induced emesis to begin this year, based on a Phase II trial published in the Jan. 21 New England Journal of Medicine ("The Pink Sheet" May 25, 1998, p. 25). A recent Phase II study in depression was "not definitive due to a high placebo response rate" but suggested activity at one dose, Merck said. The company is evaluating the development of MK-869 for depression and is commencing a Phase II trial for that indication with a backup Substance P antagonist
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




